ArticleInternational journal of molecular sciences2022
Platelet-Rich Fibrin Reduces IL-1β Release from Macrophages Undergoing Pyroptosis.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Analgesic effects of platelet-rich fibrin (PRF): A systematic review.Periodontology 2000 · 2025Pooled it
- A scoping review on platelet-rich fibrin-driven bone regeneration: biological mechanisms and clinical applications in oral and maxillofacial surgery.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2026Article
- Preclinical Evaluation of the Effect of Liquid Platelet-Rich Fibrin and a Volume-Stable Collagen Matrix on Periodontal Regeneration.Journal of clinical periodontology · 2026Article
- Transcriptomic characterization of platelet-rich fibrin-induced macrophage responses identifies U937 cells as a sensitive bioassay.Frontiers in immunology · 2026Article
- NLRP3 Inflammasome-Mediated Pyroptosis in Osteoporosis: Osteoimmune Mechanisms and Therapeutic Targeting.Journal of cellular and molecular medicine · 2025Review
- Effects of platelet-rich fibrin on repair and healing chronic refractory wounds in rats by regulating Wnt/β-catenin signalling pathway.Postepy dermatologii i alergologii · 2025Article
- How to explain the beneficial effects of platelet-rich plasma.Periodontology 2000 · 2025Review
- RNAseq of peripheral blood mononucleated cells exposed to platelet-rich fibrin and enamel matrix derivatives.Scientific reports · 2025Article
- Autologous platelet-rich fibrin enhances skin wound healing in a feline trauma model.BMC veterinary research · 2024Article
- PRF Lysates Modulate Chemokine Expression in Oral Squamous Carcinoma and Healthy Epithelial Cells.Bioengineering (Basel, Switzerland) · 2024Article
- Bone Formation and Maintenance in Oral Surgery: The Decisive Role of the Immune System-A Narrative Review of Mechanisms and Solutions.Bioengineering (Basel, Switzerland) · 2024Review
- Results of the use of human platelet-rich fibrin membrane applied on colorrhaphy in nourished and malnourished rats.Acta cirurgica brasileira · 2024Article
- Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization.Frontiers in bioengineering and biotechnology · 2024Review
- Article
- Oral Cell Lysates Reduce the Inflammatory Response of Activated Macrophages.Journal of clinical medicine · 2023Article
- Secretome of Adipose-Derived Stem Cells Cultured in Platelet Lysate Improves Migration and Viability of Keratinocytes.International journal of molecular sciences · 2023Article
- Liquid platelet-rich fibrin produced via horizontal centrifugation decreases the inflammatory response and promotes chondrocyte regenerationFrontiers in bioengineering and biotechnology · 2023Article
- Platelet, a key regulator of innate and adaptive immunity.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundPyroptosis is a catabolic process relevant to periodontal disorders for which interleukin-1β (IL-1β) inflammation is central to the pathophysiology of the disease. Despite platelet-rich fibrin (PRF) anti-inflammatory properties and its application to support periodontal regeneration, the capacity of PRF to modulate pyroptosis, specifically the production and release of IL-1β, remains unknown. The question arises whether PRF could regulate IL-1β release from macrophages in vitro.
methodsTo answer this question, RAW 264.7 macrophages and primary macrophages obtained from murine bone marrow were primed with PRF before being challenged by lipopolysaccharide (LPS). Cells were then analysed for the pyroptosis signalling components by gene expression analyses and IL-1β secretion at the protein level. The release of mitochondrial reactive oxygen species (ROS) was also detected.
resultsPRF lowered the LPS-induced expression of IL-1β and NLRP3 inflammasome, caspase-11 and IL-18 in primary macrophages, and IL-1β and caspase-11 in RAW 264.7 cells. Additionally, PRF diminished the secretion of IL-1β at the protein level in LPS-induced RAW 264.7 cells. This was shown through immunoassays performed with the supernatant and further confirmed by analysing the lysates of permeabilised cells. Furthermore, PRF reduced the ROS release provoked by LPS in RAW 264.7 cells. Finally, to enhance IL-1β release from the LPS-primed macrophages, we introduced a second signal with adenosine triphosphate (ATP). In this setting, PRF significantly reduced IL-1β release in RAW 264.7 cells and a trend to diminish IL-1β release in primary macrophages.
conclusionThese findings suggest that PRF can reduce IL-1β release and, at least in part, inhibit pyroptosis-related factors in LPS-challenged macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.